Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 3/20 | 0.46 |
| ▸ | RAB9A | P51151 | 3/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 4/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.40 |
| ▸ | VNN1 | O95497 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22623348 | 0.88 | ALDH1A1 (0.40) | ALDH1A1KDM4EHPGDHSD17B10NPC1 | |
| SCHEMBL20181614 | 0.87 | ALDH1A1 (0.50) | ALDH1A1KDM4EHPGDHSD17B10RAB9A | |
| SCHEMBL21192147 | 0.84 | KDM4E (0.48) | ALDH1A1KDM4EHPGDHSD17B10PKM | |
| SCHEMBL22623459 | 0.83 | LMNA (0.43) | ALDH1A1KDM4EHPGDRAB9ALMNA | |
| SCHEMBL21176899 | 0.83 | KDM4E (0.45) | ALDH1A1KDM4EHPGDHSD17B10LMNA | |
| SCHEMBL29638921 | 0.83 | KDM4E (0.45) | ALDH1A1KDM4EHPGDHSD17B10LMNA | |
| SCHEMBL18629838 | 0.81 | SMN1; SMN2 (0.52) | ALDH1A1KDM4EHPGDHSD17B10NPC1 | |
| SCHEMBL21191884 | 0.80 | ALDH1A1 (0.43) | ALDH1A1KDM4EHPGDHSD17B10NPC1 | |
| SCHEMBL21191881 | 0.80 | KDM4E (0.48) | ALDH1A1KDM4EHPGDHSD17B10MAPT | |
| SCHEMBL29638909 | 0.80 | ALDH1A1 (0.43) | ALDH1A1KDM4EHPGDHSD17B10NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE50083-E1 | URAT1 inhibitor and use thereof | JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO., LTD. (CN) | 2024-08-20 | — | — | US | disclosed |
| CN-117586272-A | Heterocyclic compound, preparation method and application thereof in medicine | 苏州信诺维医药科技股份有限公司 | 2024-02-23 | — | — | CN | disclosed |
| CN-111615515-B | Heterocyclic compound, preparation method and application thereof in medicine | 苏州信诺维医药科技股份有限公司 | 2023-11-24 | — | — | CN | disclosed |
| EP-3741759-B1 | IMIDAZO[1,2-A]PYRIMIDINE AND IMIDAZO[1,2-C]PYRIMIDINE COMPOUNDS AND USE THEREOF IN THE TREATMENT OF HYPERURICEMIA AND GOUT | EVOPOINT BIOSCIENCES CO LTD (CN) | 2023-08-23 | — | — | EP | disclosed |
| US-11453674-B2 | Heterocyclic compound, preparation method and use thereof in medicine | Evopoint Biosciences Co., Ltd. (CN) | 2022-09-27 | — | — | US | disclosed |
| EP-3543240-B1 | URAT1 INHIBITOR AND USE THEREOF | JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO LTD (CN) | 2022-07-06 | — | — | EP | disclosed |
| EP-3543240-B1 | URAT1 INHIBITOR AND USE THEREOF | JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO LTD (CN) | 2022-07-06 | — | — | EP | disclosed |
| CN-112979661-B | Heterocyclic compound, preparation method and application thereof in medicine | 苏州信诺维医药科技股份有限公司 | 2022-05-17 | — | — | CN | disclosed |
| US-10875865-B2 | URAT1 inhibitor and use thereof | JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO., LTD. (CN) | 2020-12-29 | — | — | US | disclosed |
| US-10875865-B2 | URAT1 inhibitor and use thereof | JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO., LTD. (CN) | 2020-12-29 | — | — | US | disclosed |
| EP-3741759-A1 | HETEROCYCLIC COMPOUND, PREPARATION METHOD AND USE THEREOF IN MEDICINE | Suzhou Sinovent Pharmaceuticals Co., Ltd. (CN) | 2020-11-25 | — | — | EP | disclosed |
| US-20200347070-A1 | HETEROCYCLIC COMPOUND, PREPARATION METHOD AND USE THEREOF IN MEDICINE | SHANGHAI PUCHI BIOMEDICAL CO., LTD. (CN) | 2020-11-05 | — | — | US | disclosed |
| US-20200347070-A1 | HETEROCYCLIC COMPOUND, PREPARATION METHOD AND USE THEREOF IN MEDICINE | SHANGHAI PUCHI BIOMEDICAL CO., LTD. (CN) | 2020-11-05 | — | — | US | disclosed |
| US-20200062763-A1 | URAT1 INHIBITOR AND USE THEREOF | JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO., LTD. (CN) | 2020-02-27 | — | — | US | disclosed |
| US-20200062763-A1 | URAT1 INHIBITOR AND USE THEREOF | JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO., LTD. (CN) | 2020-02-27 | — | — | US | disclosed |
| EP-3543240-A1 | URAT1 INHIBITOR AND USE THEREOF | Jiangsu Atom Bioscience And Pharmaceutical Co., Ltd. (CN) | 2019-09-25 | — | — | EP | disclosed |
| EP-3543240-A1 | URAT1 INHIBITOR AND USE THEREOF | Jiangsu Atom Bioscience And Pharmaceutical Co., Ltd. (CN) | 2019-09-25 | — | — | EP | disclosed |
| WO-2018090921-A1 | URAT1 INHIBITOR AND USE THEREOF | 江苏新元素医药科技有限公司 | 2018-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11453674-B2 | Heterocyclic compound, preparation method and use thereof in medicine | PAH, NLRP3, CYP11B2 | ALDH1A1 1562/4885KDM4E 2925/4885HPGD 251/4885 |
| US-20200062763-A1 | URAT1 INHIBITOR AND USE THEREOF | SLC14A1, SLC10A6, SLC10A1 | ALDH1A1 356/4885KDM4E 4224/4885HPGD 2933/4885 |
| US-10875865-B2 | URAT1 inhibitor and use thereof | SLC14A1, SLC10A6, SLC10A1 | ALDH1A1 356/4885KDM4E 4224/4885HPGD 2933/4885 |
| US-20200347070-A1 | HETEROCYCLIC COMPOUND, PREPARATION METHOD AND USE THEREOF IN MEDICINE | PAH, NLRP3, CYP11B2 | ALDH1A1 1562/4885KDM4E 2925/4885HPGD 251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.